Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

Arthritis care & research - 1 Feb 2015

Park Dong-Jin, Kang Ji-Hyoun, Lee Jeong-Won, Lee Kyung-Eun, Wen Lihui, Kim Tae-Jong, Park Yong-Wook, Park Sung-Hwan, Lee Shin-Seok

Abstract excerpt

OBJECTIVE: Allopurinol-induced severe cutaneous adverse reactions (SCARs) are relatively rare but cause high rates of morbidity and mortality. Studies have shown that the HLA-B5801 allele and renal impairment are strongly associated with SCARs. Recent American College of Rheumatology guidelines recommend that, prior to treatment with allopurinol, the HLA-B5801 genotype of gout patients at high risk for SCARs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Trees

Share to Drug Eruptions

Share to Gout Suppressants

Share to HLA-B Antigens

Share to Renal Insufficiency, Chronic

Source

Identifiers

PMID: 25047754
DOI: 10.1002/acr.22409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.PMID 25047754Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Semantic proximity Read ↗

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.Semantic proximity Read ↗

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.Semantic proximity Read ↗

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.Semantic proximity Read ↗

An Updated Economic Evaluation of HLA ‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in ThailandSemantic proximity Read ↗

A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of ChinaSemantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.